Zoono Group Limited (AU:ZNO) has released an update.
Zoono Group Limited, a global biotech company specializing in long-lasting antimicrobial solutions, reported a significant downturn in its financial results, with revenues plummeting by 68.6% to NZ$1,049,321 and a striking increase in losses to NZ$9,185,193 for the fiscal year ended June 30, 2024. The company, known for its innovative ‘ZOONO molecule’ products, has decided not to pay a dividend for 2024, reflecting its challenging financial performance.
For further insights into AU:ZNO stock, check out TipRanks’ Stock Analysis page.